FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the ...

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.

The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...

The US Food and Drug Administration (FDA) has approved use of the vaccine Yeztugo, manufactured by Gilead Sciences, is an anti-HIV drug.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

General, Winnie Byanyima, has called for a drastic and transparent reduction in the cost of lenacapavir, a twice-yearly ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

The FDA has approved Yeztugo, a twice-yearly HIV injection by Gilead shown to virtually eliminate new infections.

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...